Pinpoint Asset Management LTD Bei Gene, Ltd. Transaction History

Pinpoint Asset Management LTD

  • $395 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$141.8 - $181.47 $751,540 - $961,791
5,300 New
5,300 $828,000
Q3 2023

Nov 13, 2023
BUY
$179.87 - $225.13 $618,033 - $773,546
3,436 Added 83.85%
7,534 $1.36 Million
Q2 2023

Aug 14, 2023
BUY
$178.3 - $266.78 $730,673 - $1.09 Million
4,098 New
4,098 $730,000

Others Institutions Holding BGNE

# of Institutions
253
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Pinpoint Asset Management LTD Portfolio

Follow Pinpoint Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinpoint Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinpoint Asset Management LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email